Faes Farma (FAE.MC)

Executive Summary

Faes Farma is a vertically integrated Spanish pharmaceutical company with over 90 years of history, generating €627 million in revenue (2025) and a market capitalization of $1.43 billion. The company specializes in small molecule drugs for human health and animal nutrition, with a strong global presence across 130+ countries. Its flagship product, Bilastine (for allergic rhinitis and urticaria), remains a key revenue driver, while the pipeline includes late-stage assets such as Mesalazine for ulcerative colitis (Phase 3). Faes Farma continues to invest in R&D and sustainable innovation, leveraging its chemical synthesis expertise to develop and commercialize differentiated therapies. With eight commercial products and a track record of successful launches, the company is well-positioned for steady growth. Looking ahead, Faes Farma’s near-term growth hinges on the successful completion and potential regulatory filing of its Mesalazine Phase 3 trial for ulcerative colitis. The company also has opportunities to expand Bilastine into new formulations (e.g., ophthalmic solution) and geographies. While the pipeline is relatively mature, continued execution in existing markets and cost discipline should support margin expansion. Overall, Faes Farma represents a stable, mid-cap pharma play with moderate upside from pipeline catalysts.

Upcoming Catalysts (preview)

• Q3 2026Mesalazine Phase 3 Data Readout for Ulcerative Colitis60% success